Clinical Trial Update: A Study Comparing Once-weekly vs Twice-weekly Carfilzomib in Combination With Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma [Phase 3]

View source ↗

Summary

Phase 3 trial comparing once-weekly versus twice-weekly carfilzomib in combination with lenalidomide and dexamethasone for relapsed or refractory multiple myelo…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Carfilzomib (carfilzomib)
• DEXAMETHASONE (Dexamethasone)
• Lenalidomide (lenalidomide)

Snippet

Sponsor: Amgen | Conditions: Relapsed or Refractory Multiple Myeloma | Phase 3 | Status: COMPLETED | Results posted: 2024-04-18